PURPOSE: Micrometastatic cells detected in the bone marrow have prognostic significance in breast cancer. These cells are heterogeneous and likely do not exhibit uniform biological behavior. To understand the molecular diversity of disseminated cancer cells that reside in bone marrow, we enriched this cell population and did global gene expression profiling in the context of a prospective clinical trial involving women with clinical stage II/III breast cancer undergoing neoadjuvant chemotherapy. EXPERIMENTAL DESIGN: Enrichment of TACSTD1 (EpCAM)-expressing cells from bone marrow of breast cancer patients was achieved using immunomagnetic beads. Gene expression profiles were compared between enriched cell populations and whole bone marrow from 5 normal volunteers and 23 breast cancer patients after neoadjuvant chemotherapy treatment. Enriched cells from bone marrow samples of breast cancer patients before treatment or at 1 year follow-up were also analyzed (total of 87 data sets). The expression of transcripts specifically detected in enriched cell populations from breast cancer patients was correlated with 1-year clinical outcome using quantitative reverse transcription-PCR in an independent cohort of bone marrow samples. RESULTS: Analysis of EpCAM-enriched bone marrow cells revealed specific expression of a subgroup of transcripts, including the metastasis regulator, TWIST1. Most transcripts identified, including TWIST1, were not expressed in enriched populations of bone marrow from normal volunteers, suggesting that this expression profile reflects a signature of breast cancer bone marrow micrometastases that persist after chemotherapy. In an independent set of bone marrow samples obtained before any treatment, TWIST1 expression correlated with early disease relapse. CONCLUSIONS: Disseminated breast cancer cells present in bone marrow after chemotherapy possess unique transcriptional signatures. Genes whose expression is overrepresented in these cell populations, such as TWIST1, may prove to be excellent markers of early distant relapse in breast cancer patients.
PURPOSE: Micrometastatic cells detected in the bone marrow have prognostic significance in breast cancer. These cells are heterogeneous and likely do not exhibit uniform biological behavior. To understand the molecular diversity of disseminated cancer cells that reside in bone marrow, we enriched this cell population and did global gene expression profiling in the context of a prospective clinical trial involving women with clinical stage II/III breast cancer undergoing neoadjuvant chemotherapy. EXPERIMENTAL DESIGN: Enrichment of TACSTD1 (EpCAM)-expressing cells from bone marrow of breast cancerpatients was achieved using immunomagnetic beads. Gene expression profiles were compared between enriched cell populations and whole bone marrow from 5 normal volunteers and 23 breast cancerpatients after neoadjuvant chemotherapy treatment. Enriched cells from bone marrow samples of breast cancerpatients before treatment or at 1 year follow-up were also analyzed (total of 87 data sets). The expression of transcripts specifically detected in enriched cell populations from breast cancerpatients was correlated with 1-year clinical outcome using quantitative reverse transcription-PCR in an independent cohort of bone marrow samples. RESULTS: Analysis of EpCAM-enriched bone marrow cells revealed specific expression of a subgroup of transcripts, including the metastasis regulator, TWIST1. Most transcripts identified, including TWIST1, were not expressed in enriched populations of bone marrow from normal volunteers, suggesting that this expression profile reflects a signature of breast cancer bone marrow micrometastases that persist after chemotherapy. In an independent set of bone marrow samples obtained before any treatment, TWIST1 expression correlated with early disease relapse. CONCLUSIONS: Disseminated breast cancer cells present in bone marrow after chemotherapy possess unique transcriptional signatures. Genes whose expression is overrepresented in these cell populations, such as TWIST1, may prove to be excellent markers of early distant relapse in breast cancerpatients.
Authors: W Janni; F Hepp; D Rjosk; C Kentenich; B Strobl; C Schindlbeck; P Hantschmann; H Sommer; K Pantel; S Braun Journal: Cancer Date: 2001-07-01 Impact factor: 6.860
Authors: Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Ronald Simon; Hanspeter Spichtin; Robert Maurer; Urs Metzger; Brida von Castelberg; Rahel Bart; Shanna Stopatschinskaya; Ossi Robert Köchli; Philip Haas; Friedrich Mross; Markus Zuber; Holger Dietrich; Susanne Bischoff; Martina Mirlacher; Guido Sauter; Guenther Gastl Journal: Breast Cancer Res Treat Date: 2004-08 Impact factor: 4.872
Authors: Christoph A Klein; Stefan Seidl; Karina Petat-Dutter; Sonja Offner; Jochen B Geigl; Oleg Schmidt-Kittler; Nicole Wendler; Bernward Passlick; Rudolf M Huber; Günter Schlimok; Patrick A Baeuerle; Gert Riethmüller Journal: Nat Biotechnol Date: 2002-04 Impact factor: 54.908
Authors: Bryan E Welm; Stacey B Tepera; Teresa Venezia; Timothy A Graubert; Jeffrey M Rosen; Margaret A Goodell Journal: Dev Biol Date: 2002-05-01 Impact factor: 3.582
Authors: Maria C Elias; Kathleen R Tozer; John R Silber; Svetlana Mikheeva; Mei Deng; Richard S Morrison; Thomas C Manning; Daniel L Silbergeld; Carlotta A Glackin; Thomas A Reh; Robert C Rostomily Journal: Neoplasia Date: 2005-09 Impact factor: 5.715
Authors: Pushkar A Phadke; Robyn R Mercer; John F Harms; Yujiang Jia; Andra R Frost; Jennifer L Jewell; Karen M Bussard; Shakira Nelson; Cynthia Moore; John C Kappes; Carol V Gay; Andrea M Mastro; Danny R Welch Journal: Clin Cancer Res Date: 2006-03-01 Impact factor: 12.531
Authors: Tony Blick; Honor Hugo; Edwin Widodo; Mark Waltham; Cletus Pinto; Sendurai A Mani; Robert A Weinberg; Richard M Neve; Marc E Lenburg; Erik W Thompson Journal: J Mammary Gland Biol Neoplasia Date: 2010-06-04 Impact factor: 2.673
Authors: David D Tran; Callie Ann S Corsa; Hirak Biswas; Rebecca L Aft; Gregory D Longmore Journal: Mol Cancer Res Date: 2011-10-17 Impact factor: 5.852
Authors: Lorenz C Hofbauer; Aline Bozec; Martina Rauner; Franz Jakob; Sven Perner; Klaus Pantel Journal: Nat Rev Clin Oncol Date: 2021-04-19 Impact factor: 66.675